ALKS — Alkermes plc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1520262 ·
Last close
$51.94
Market Cap
$8.66B
52W High
$55.67
52W Low
$32.76
ADV30
2,563,841
Next earnings
2026-07-28
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 392,911,000 331,333,000 -48,280,000 -66,480,000 4,258,076,000 351,551,000 2,506,545,000
Dec 2025 384,547,000 338,338,000 58,104,000 49,341,000 2,486,993,000 388,570,000 667,698,000
Sep 2025 394,185,000 342,594,000 89,082,000 82,761,000 2,329,512,000 616,449,000 596,080,000
Jun 2025 390,657,000 341,197,000 92,978,000 87,098,000 2,252,809,000 521,199,000 628,225,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$256,200,000
Investing CF
$-1,790,605,000
Financing CF
$1,486,151,000
CapEx
$-44,530,000
Dividends Paid
Buybacks
$-27,696,000
EPS Diluted TTM
$0.90
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-801,274,000
Inventory
$336,703,000
Receivables
$407,630,000
ST Investments
$160,311,000
EBIT TTM
$237,204,000
Pretax Income TTM
$204,035,000
Interest Exp TTM
$33,169,000
Analysts
17

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,562,300,032
EBITDA
$278,583,008
Free Cash Flow
$140,551,632
Enterprise Value
$10,033,623,040
Total Cash
$511,862,016
Total Debt
$1,581,660,032
Shares Out
166,675,807
Trailing EPS
$0.90
Book Value
$10.52
ROE
9.4%
ROA
4.7%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 1,475,899,000 253,956,000 241,664,000 2,486,993,000 667,698,000 520,754,000
Dec 2024 1,557,632,000 420,636,000 367,070,000 2,055,567,000 590,590,000 439,124,000
Dec 2023 1,663,405,000 414,122,000 355,757,000 2,136,223,000 933,537,000 401,353,000
Dec 2022 1,111,795,000 -6,089,000 -158,267,000 1,963,978,000 920,225,000 21,044,000

TTM Snapshot

Revenues TTM
$399,082,000
NetIncome TTM
$-105,686,000
OpCashFlow TTM
$0
Assets (Latest)
$1,797,227,000
Forward EPS
$1.56

Max Pain — expiry 2026-08-21

max pain strike: $45.00 · spot: $51.94 · call oi: 6,866 · put oi: 5,549
Expected Move to 2026-08-21: ±$6.97 (13.43%) — implied range $44.96$58.91 · ATM straddle on $50.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
TGTX TG THERAPEUTICS, INC. $8.74B $57.12
SYRE Spyre Therapeutics, Inc. $8.49B $97.74
CRNX Crinetics Pharmaceuticals, Inc. $8.85B $83.58
PTGX Protagonist Therapeutics, Inc $8.45B $131.42
PRAX Praxis Precision Medicines, Inc. $9.06B $324.99

News headlines (Yahoo Finance, 1h cache)

Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar?
2026-07-03 11:06 · Yahoo
Alkermes (ALKS) Is Up 9.3% After Strong Alixorexton Phase 2 Data And Russell 2000 Addition - What's Changed
2026-06-30 14:07 · Yahoo
Sector Update: Healthcare Stocks Higher Late Afternoon
2026-06-29 19:59 · Yahoo
Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation?
2026-06-29 17:41 · Yahoo
HRMY Growth Trends Beyond Wakix Could Shape Its Next Growth Phase
2026-06-29 17:40 · Yahoo
BofA cuts ratings on four biopharma stocks over valuation and catalyst concerns
2026-06-29 16:01 · Yahoo
Alkermes Faces Risk on Orexin-Related Value From Upcoming Updates, BofA Says
2026-06-29 15:14 · Yahoo
Adobe downgraded, Roblox upgraded: Wall Street's top analyst calls
2026-06-29 13:44 · Yahoo
Here Are Monday’s Best Wall Street Analyst Research Calls: Adobe, Applovin, Casey’s General Stores, CrowdStrike, Honeywell Aerospace, Salesforce, Synaptics, Terawulf, and More
2026-06-29 12:21 · Yahoo
Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda
2026-06-26 09:46 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.